Associations between EBV serostatus and organ transplant type in PTLD risk: An analysis of the SRTR national registry data in the United States

American Journal of Transplantation

Volumn 12, Issue 4, 2012, Pages 976-983

  Dharnidharka, Vikas R ^a   Lamb, K E ^a,b   Gregg, J A ^a   Meier Kriesche, H U ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Epstein Barr virus; Heart transplant; Kidney transplant; Liver transplant; PTLD

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; MYCOPHENOLIC ACID; TACROLIMUS;

ADULT; ARTICLE; CAUCASIAN; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORGAN TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SERODIAGNOSIS; T LYMPHOCYTE; UNITED STATES;

ADOLESCENT; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; MALE; REGISTRIES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SURVIVAL RATE; TRANSPLANTS; UNITED STATES;

EID: 84859311382     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03893.x     Document Type: Article

References (28)

1. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80(Suppl 9): 1233-1243. (Pubitemid 41746802)
2. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Posttransplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56(Suppl 1): 88-96.
3. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8(Suppl 5): 984-989. (Pubitemid 351537758)
4. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and NewZealand. Transplantation 2005; 80(Suppl 2): 193-197. (Pubitemid 41061675)
5. Funch DP, Ko HH, Travasso J, et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 2005; 80(Suppl 9): 1174-1180. (Pubitemid 41746793)
6. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7(Suppl 11): 2619-2625. (Pubitemid 47561615)
7. Katz BZ, Pahl E, Crawford SE, et al. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr Transplant 2007; 11(Suppl 1): 58-65. (Pubitemid 46100956)
8. Mendoza F, Kunitake H, Laks H, Odim J. Post-transplant lymphoproliferative disorder following pediatric heart transplantation. Pediatr Transplant 2006; 10(Suppl 1): 60-66.
9. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14(Suppl 2): 214-221.
10. Opelz G, Daniel V, Naujokat C, Dohler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88(Suppl 8): 962-967.
11. Dharnidharka VR. Epidemiology of PTLD. In: Dharnidharka VR, Green M, Webber SA, eds. Post-Transplant Lymphoproliferative Disorders. Berlin: Springer-Verlag, 2009, pp. 17-28.
12. Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol 2009; 24(Suppl 4): 731-736.
13. Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 2006; 6(Suppl 11): 2735-2742. (Pubitemid 44571695)
14. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59(Suppl 4): 524-529.
15. Kremers WK, Devarbhavi HC,Wiesner RH, Krom RA, MaconWR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: Incidence, risk factors and survival. Am J Transplant 2006; 6:1017-1024. (Pubitemid 44356653)
16. Duvoux C, Pageaux GP, Vanlemmens C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: An analysis of 480 patients. Transplantation 2002; 74(Suppl 8): 1103-1109. (Pubitemid 35216103)
17. Shepherd RW, Turmelle Y, Nadler M, et al. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant 2008; 8(Suppl 2): 396-403.
18. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62(Suppl 3): 370-375.
19. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein- Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64(Suppl 10): 1438-1442. (Pubitemid 27513623)
20. Badley AD, Portela DF, Patel R, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virusinduced posttransplant lymphoproliferative disorder. Liver Transpl Surg 1996; 2: 375-382. (Pubitemid 26303927)
21. Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004; 40: 728-735. (Pubitemid 38507351)
22. Zein NN, Perez RG, Wiesner RH. Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation. Hepatology 2000; 31: 808-809. (Pubitemid 30118658)
23. Wu L, Rappaport DC, Hanbidge A, Merchant N, Shepherd FA, Greig PD. Lymphoproliferative disorders after liver transplantation: Imaging features. Abdom Imaging 2001; 26(Suppl 2): 200-206. (Pubitemid 32187128)
24. Marino D, Burra P, Boccagni P, et al. Post-transplant lymphoproliferative disorders in liver transplanted patients: A single-centre experience. Anticancer Res 2010; 30(Suppl 6): 2383-2391.
25. Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A. Posttransplantation lymphoproliferative disorder - The great mimic in liver transplantation: Appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007; 13(Suppl 6): 904-912. (Pubitemid 46947851)
26. Patel H, Vogl DT, Aqui N, et al. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: A report of seventeen cases. Leuk Lymphoma 2007; 48(Suppl 5): 885-891. (Pubitemid 47161559)
27. Hezode C, Duvoux C, Germanidis G, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 1999; 30(Suppl 3): 775-778. (Pubitemid 29409423)
28. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease. J Infect Dis 1997; 176(Suppl 6): 1462-1467. (Pubitemid 27518144)